Cargando…

Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study

BACKGROUND: An artificial-tear formulation containing the dual polymers hydroxypropyl guar (HPG) and hyaluronic acid (HA) is approved for the treatment of dry-eye disease (DED). The present study compared the efficacy and safety of the HPG-HA dual-polymer formulation vs a sodium hyaluronate (SH)-con...

Descripción completa

Detalles Bibliográficos
Autores principales: Labetoulle, Marc, Schmickler, Stefanie, Galarreta, David, Böhringer, Daniel, Ogundele, Abayomi, Guillon, Michel, Baudouin, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287663/
https://www.ncbi.nlm.nih.gov/pubmed/30584269
http://dx.doi.org/10.2147/OPTH.S177176
_version_ 1783379676617506816
author Labetoulle, Marc
Schmickler, Stefanie
Galarreta, David
Böhringer, Daniel
Ogundele, Abayomi
Guillon, Michel
Baudouin, Christophe
author_facet Labetoulle, Marc
Schmickler, Stefanie
Galarreta, David
Böhringer, Daniel
Ogundele, Abayomi
Guillon, Michel
Baudouin, Christophe
author_sort Labetoulle, Marc
collection PubMed
description BACKGROUND: An artificial-tear formulation containing the dual polymers hydroxypropyl guar (HPG) and hyaluronic acid (HA) is approved for the treatment of dry-eye disease (DED). The present study compared the efficacy and safety of the HPG-HA dual-polymer formulation vs a sodium hyaluronate (SH)-containing artificial-tear formulation in patients with DED. METHODS: In a prospective, 6-week, multicenter, double-masked, parallel-group study, patients with DED aged ≥18 years and total ocular surface staining (TOSS) score ≥4 and ≤9 were randomized (1:1) to receive either HPG-HA or SH four times a day for 42 days. Changes from baseline in TOSS (primary end point), impact of dry eye on everyday life (IDEEL) treatment-satisfaction scores (effectiveness and inconvenience), and tear-film breakup time (TFBUT) at day 42 were assessed using a fixed-sequence testing strategy. Noninferiority was assessed on the primary end point based on the upper limit of two-sided 95% CIs for mean treatment difference (HPG-HA or SH) <2 units. RESULTS: In total, 99 patients were randomized (HPG-HA, n= 50; SH, n= 49). At day 42, the least square (LS) mean ± SE change from baseline in TOSS was −1.16±0.24 and −0.92±0.23 in the HPG-HA and SH groups, respectively, and the treatment difference was −0.24±0.33 (95% CI −0.90 to 0.42). Noninfe-riority was demonstrated as the upper limit of the 95% CI was <2 units. LS mean change from baseline at day 42 for HPG-HA vs SH was −3.18 (P=0.4817) in IDEEL treatment-effectiveness scores, −12.56 (P=0.0001) in treatment-inconvenience scores, and 0.30 seconds (P=0.5789) in TFBUT. CONCLUSION: The HPG-HA dual-polymer formulation was noninferior to the SH lubricant eye-drops for improvement in ocular surface staining in DED. HPG-HA did not show improvement over SH in IDEEL treatment-satisfaction scores. No new safety findings were reported.
format Online
Article
Text
id pubmed-6287663
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62876632018-12-24 Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study Labetoulle, Marc Schmickler, Stefanie Galarreta, David Böhringer, Daniel Ogundele, Abayomi Guillon, Michel Baudouin, Christophe Clin Ophthalmol Original Research BACKGROUND: An artificial-tear formulation containing the dual polymers hydroxypropyl guar (HPG) and hyaluronic acid (HA) is approved for the treatment of dry-eye disease (DED). The present study compared the efficacy and safety of the HPG-HA dual-polymer formulation vs a sodium hyaluronate (SH)-containing artificial-tear formulation in patients with DED. METHODS: In a prospective, 6-week, multicenter, double-masked, parallel-group study, patients with DED aged ≥18 years and total ocular surface staining (TOSS) score ≥4 and ≤9 were randomized (1:1) to receive either HPG-HA or SH four times a day for 42 days. Changes from baseline in TOSS (primary end point), impact of dry eye on everyday life (IDEEL) treatment-satisfaction scores (effectiveness and inconvenience), and tear-film breakup time (TFBUT) at day 42 were assessed using a fixed-sequence testing strategy. Noninferiority was assessed on the primary end point based on the upper limit of two-sided 95% CIs for mean treatment difference (HPG-HA or SH) <2 units. RESULTS: In total, 99 patients were randomized (HPG-HA, n= 50; SH, n= 49). At day 42, the least square (LS) mean ± SE change from baseline in TOSS was −1.16±0.24 and −0.92±0.23 in the HPG-HA and SH groups, respectively, and the treatment difference was −0.24±0.33 (95% CI −0.90 to 0.42). Noninfe-riority was demonstrated as the upper limit of the 95% CI was <2 units. LS mean change from baseline at day 42 for HPG-HA vs SH was −3.18 (P=0.4817) in IDEEL treatment-effectiveness scores, −12.56 (P=0.0001) in treatment-inconvenience scores, and 0.30 seconds (P=0.5789) in TFBUT. CONCLUSION: The HPG-HA dual-polymer formulation was noninferior to the SH lubricant eye-drops for improvement in ocular surface staining in DED. HPG-HA did not show improvement over SH in IDEEL treatment-satisfaction scores. No new safety findings were reported. Dove Medical Press 2018-12-05 /pmc/articles/PMC6287663/ /pubmed/30584269 http://dx.doi.org/10.2147/OPTH.S177176 Text en © 2018 Labetoulle et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Labetoulle, Marc
Schmickler, Stefanie
Galarreta, David
Böhringer, Daniel
Ogundele, Abayomi
Guillon, Michel
Baudouin, Christophe
Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
title Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
title_full Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
title_fullStr Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
title_full_unstemmed Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
title_short Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
title_sort efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287663/
https://www.ncbi.nlm.nih.gov/pubmed/30584269
http://dx.doi.org/10.2147/OPTH.S177176
work_keys_str_mv AT labetoullemarc efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy
AT schmicklerstefanie efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy
AT galarretadavid efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy
AT bohringerdaniel efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy
AT ogundeleabayomi efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy
AT guillonmichel efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy
AT baudouinchristophe efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy